For patients with BRAF wild-type and BRAF V600-mutant melanoma, the objective response rate was 39.8% (447/1124) and 34.3% (149/434), 4-year progression-free survival rate was 22.9% (257/1124) and 19.8% (86/434), and 4-year overall survival was 37.5% (421/1124) and 35.1% (152/434), respectively. This evidence concerns the gene BRAF and melanoma.